

**Drug Utilization Review Board
 Meeting Minutes
 Tuesday, November 15, 2022**

DRAFT document with pending approval at the next meeting

The Nebraska Drug Utilization Review (DUR) Board met Tuesday November 15, 2022. at the Country Inn Suites in Lincoln, Nebraska.

DUR Board Members in attendance in person: Tim Bourke, R.P.; Tom Dunn, R.P.; Anthony Ross, M.D.

DUR Board Members not in attendance: Susan Howard, M.D.; Robert Wergin, M.D.; Bruce Houghton, M.D.; Charlie Moore, R.P.; David Randolph, R.P.

DHHS attendees: Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P.; Ken Saunders, R.P., Director of Pharmacy

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Shannon Nelson, R.P., Nebraska HealthyBlue; Bernadette Ueda, R.P., United Health Care; Nikia Bennette-Carter, R.P., Magellan RX Management; and Elanah Figueroa Account Manager, Magellan RX Management

Public members in attendance: Erin Hohman, R.P.; Audrey Ratton, R.P., Abbvie; Melissa Basil, Abbvie; Erin Hohman, Abbvie; Camille Kerr, Regeneron; Kurt Hendrickson, Abbvie; Dee Humm, Genentech; Keith Gulley, Amgen; Gina Heinen, Novo Nordisk; Randall Roth, Merck; Marc Parker, Sunovion; Craig Bloom, CSL Vifor; Donna Osterlund, Sanofi; Gary Parenteau, Dexcom

I. Openings and Introductions

The meeting was called to order by Ken Saunders at 6:33 PM CST. The OpenMeetings Act was available. A quorum was not established at the beginning of the meeting.

II. Conflict of Interest

Saunders called for declaration of conflicts of interest. None were declared.

III. Agenda approval

Because there was not a quorum, the Agenda could not be voted upon. No changes to the agenda were made.

IV. Meeting Minutes from May 2022, July 2022, September 2022

A quorum was not established at the beginning of the meeting. No corrections were made to draft minutes. No vote may be taken.

V. Drug Review

The Immunomodulators: Self-Administered Injectables Prior Authorization form was presented and reviewed. The Growth Hormone Criteria and Prior Authorization Forms were also reviewed and discussed.

VI. DUR Topics

A review of SUPPORT Act utilization of opioids concurrently with benzodiazepines, antipsychotics, and gabapentin/pregabalin data was presented.

Data was presented on members who were prescribed Lithium and had a claim for a lithium serum level within the last six months.

VII. Future Meeting Date

The next DUR Board Meeting is scheduled for Tuesday, January 10, 2023.

VIII. Concerns & Comments

Board: none.

Magellan representatives: Proposed that meetings be virtual only. A suggestion of diabetes as a future DUR topic was made. The State countered that the Open Meetings Act authorizes one-half of their meetings by virtual conferencing annually.

DHHS: Saunders commented on data criteria in the future.

MCO Representatives: none

IX. Adjournment

The DUR Board adjourned at 7:42 PM. No vote was taken.